Well Referenced

Tag: Immunology

mTOR inhibition improves antitumor effects of vaccination with antigen-encoding RNA

This 2013 study by Diken et al. explored the synergistic potential of combining mTOR inhibition with RNA-based cancer vaccination. Utilizing a B16 melanoma model expressing ovalbumin in C57BL/6 mice, researchers administered intranodal injections of in vitro transcribed RNA encoding the tumor antigen, followed by rapamycin treatment during the effector-to-memory transition

Read More »
June 26, 2025 No Comments

Potential Therapeutic Benefit of Low Dose Naltrexone in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Role of Transient Receptor Potential Melastatin 3 Ion Channels in Pathophysiology and Treatment

This 2021 review article, published in Frontiers in Immunology, explores the potential therapeutic role of low-dose naltrexone (LDN) in treating Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). The authors discuss how LDN, typically administered at doses of 1.5 to 4.5 mg daily, may alleviate ME/CFS symptoms by modulating the Transient Receptor Potential

Read More »
June 26, 2025 No Comments

Rapamycin has suppressive and stimulatory effects on human plasmacytoid dendritic cell functions

This 2013 study by Boor et al. examined how rapamycin, an mTOR inhibitor, modulates the functions of human plasmacytoid dendritic cells (pDCs), which are pivotal in both innate and adaptive immunity. At clinically relevant concentrations, rapamycin significantly suppressed Toll-like receptor 7 (TLR7)-induced interferon-alpha (IFN-α) production by 64% and modestly reduced

Read More »
June 26, 2025 No Comments

Rejuvenating immunity: “anti-aging drug today” eight years later

In this 2015 commentary, Mikhail V. Blagosklonny reflects on the potential of rapamycin as an anti-aging agent, particularly its role in rejuvenating the immune system. He discusses how rapamycin, an mTOR inhibitor, has been shown to delay aging and extend lifespan in various animal models by modulating immune function and

Read More »
June 26, 2025 No Comments

Interaction of opioid growth factor (OGF) and opioid antagonist and their significance in cancer therapy

This 2019 review article, published in International Immunopharmacology, examines the role of the opioid growth factor (OGF)–OGF receptor (OGFr) axis in cancer therapy. OGF, identified as [Met5]-enkephalin, is an endogenous peptide that binds to OGFr to regulate cell proliferation by inhibiting DNA synthesis. The review discusses how low-dose naltrexone (LDN),

Read More »
June 26, 2025 No Comments

Low dose naltrexone for induction of remission in Crohn’s disease

This 2014 Cochrane systematic review assessed the efficacy and safety of low-dose naltrexone (LDN) for inducing remission in Crohn’s disease. Two randomized controlled trials were included: one involving 34 adults receiving 4.5 mg/day of LDN for 12 weeks, and another with 12 pediatric patients administered 0.1 mg/kg (up to 4.5

Read More »
June 26, 2025 No Comments

Low dose Naltrexone for induction of remission in inflammatory bowel disease patients

This 2018 prospective cohort study, published in the Journal of Translational Medicine, assessed the efficacy of low-dose naltrexone (LDN) in inducing remission among therapy-refractory inflammatory bowel disease (IBD) patients. Forty-seven individuals with active Crohn’s disease or ulcerative colitis, unresponsive to standard treatments, received 4.5 mg of LDN nightly for 12

Read More »
June 26, 2025 No Comments